High-throughput sequencing services such as whole-genome sequencing and whole-exome sequencing cover clinical applications such as genetic disease screening, tumor genomics, and pathogenic microorganism detection. Equipped with an independent sequencing platform (DNBSEQ™), it supports large-scale, low-cost, and high-precision sequencing

TargetCap® targeted capture chip covers multiple omics applications such as DNA-Cap, RNA-Cap, Methyl-Cap, Pathogen-Cap, etc. It is suitable for genetic diseases, tumors, cardiovascular diseases, pathogen detection, and other scenarios. It supports personalized Panel customization and is compatible with mainstream sequencing platforms such as Illumina, MGI, and Nanopore. It has full-process domestic production capabilities, and the probe synthesis and chip performance are at the international leading level

Possessing internationally competitive capabilities in the research, development, and production of innovative and generic drugs. Our products have been certified by the US FDA and meet international quality and safety standards. We have a subsidiary in the United States, providing localized supply and regulatory support capabilities

Provide a fully automated chemiluminescence immunoassay system with a rapid detection mode (STAT) that can produce results within 7 minutes, suitable for use in tertiary hospitals, children's hospitals, third-party testing centers, and other scenarios

Our main products include pharmaceutical preparations, active pharmaceutical ingredients, and intermediates, forming a distinctive product pattern dominated by cardiovascular drugs, antidepressants, and antiviral drugs, with a focus on refinement, refinement, and strength, and a series of large-scale development.